200 related articles for article (PubMed ID: 34088994)
21. Hypothalamic connectivities predict individual differences in ADT-elicited changes in working memory and quality of life in prostate cancer patients.
Chaudhary S; Roy A; Summers C; Zhornitsky S; Ahles T; Li CR; Chao HH
Sci Rep; 2022 Jun; 12(1):9567. PubMed ID: 35688928
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function.
Reiss AB; Saeedullah U; Grossfeld DJ; Glass AD; Pinkhasov A; Katz AE
Clin Transl Oncol; 2022 May; 24(5):733-741. PubMed ID: 34743290
[TBL] [Abstract][Full Text] [Related]
23. Genetic Risk for Age-Related Cognitive Impairment Does Not Predict Cognitive Performance in Middle Age.
Korthauer LE; Awe E; Frahmand M; Driscoll I
J Alzheimers Dis; 2018; 64(2):459-471. PubMed ID: 29865048
[TBL] [Abstract][Full Text] [Related]
24. Effects of androgen deprivation on cerebral morphometry in prostate cancer patients--an exploratory study.
Chao HH; Hu S; Ide JS; Uchio E; Zhang S; Rose M; Concato J; Li CS
PLoS One; 2013; 8(8):e72032. PubMed ID: 23977199
[TBL] [Abstract][Full Text] [Related]
25. The Confusion Surrounding Androgen Deprivation Therapy and Cognitive Dysfunction.
Pierro MJ; Kilari D
Eur Urol Focus; 2023 May; 9(3):409-410. PubMed ID: 37005166
[TBL] [Abstract][Full Text] [Related]
26. Dissociation of event-based prospective memory and time-based prospective memory in patients with prostate cancer receiving androgen-deprivation therapy: a neuropsychological study.
Yang J; Zhong F; Qiu J; Cheng H; Wang K
Eur J Cancer Care (Engl); 2015 Mar; 24(2):198-204. PubMed ID: 25711542
[TBL] [Abstract][Full Text] [Related]
27. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids.
García-Fontana B; Morales-Santana S; Varsavsky M; García-Martín A; García-Salcedo JA; Reyes-García R; Muñoz-Torres M
Osteoporos Int; 2014 Feb; 25(2):645-51. PubMed ID: 23903956
[TBL] [Abstract][Full Text] [Related]
28. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment.
Amidi A; Agerbæk M; Wu LM; Pedersen AD; Mehlsen M; Clausen CR; Demontis D; Børglum AD; Harbøll A; Zachariae R
Brain Imaging Behav; 2017 Jun; 11(3):769-783. PubMed ID: 27240852
[TBL] [Abstract][Full Text] [Related]
29. Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment.
Vaiana AM; Chen Y; Gelfond J; Johnson-Pais TL; Leach RJ; Ramamurthy C; Thompson IM; Morilak DA
Transl Psychiatry; 2023 Oct; 13(1):307. PubMed ID: 37788996
[TBL] [Abstract][Full Text] [Related]
30. Vortioxetine Reverses Impairment of Visuospatial Memory and Cognitive Flexibility Induced by Degarelix as a Model of Androgen Deprivation Therapy in Rats.
Vaiana AM; Asher AM; Tapia K; Morilak DA
Neuroendocrinology; 2024; 114(3):279-290. PubMed ID: 38104552
[TBL] [Abstract][Full Text] [Related]
31. Associations of Cigarette Smoking and Polymorphisms in Brain-Derived Neurotrophic Factor and Catechol-O-Methyltransferase with Neurocognition in Alcohol Dependent Individuals during Early Abstinence.
Durazzo TC; Hutchison KE; Fryer SL; Mon A; Meyerhoff DJ
Front Pharmacol; 2012; 3():178. PubMed ID: 23087644
[TBL] [Abstract][Full Text] [Related]
32. Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.
Cherrier MM; Cross DJ; Higano CS; Minoshima S
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):394-402. PubMed ID: 29700388
[TBL] [Abstract][Full Text] [Related]
33. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers.
Ho BC; Milev P; O'Leary DS; Librant A; Andreasen NC; Wassink TH
Arch Gen Psychiatry; 2006 Jul; 63(7):731-40. PubMed ID: 16818862
[TBL] [Abstract][Full Text] [Related]
34. Gut environment changes due to androgen deprivation therapy in patients with prostate cancer.
Kure A; Tsukimi T; Ishii C; Aw W; Obana N; Nakato G; Hirayama A; Kawano H; China T; Shimizu F; Nagata M; Isotani S; Muto S; Horie S; Fukuda S
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):323-330. PubMed ID: 35418210
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
36. Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study.
Timilshina N; Hussain S; Breunis H; Alibhai SM
Support Care Cancer; 2011 Nov; 19(11):1815-21. PubMed ID: 20953801
[TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation therapy increases brain ageing.
Plata-Bello J; Plata-Bello A; Pérez-Martín Y; Fajardo V; Concepción-Massip T
Aging (Albany NY); 2019 Aug; 11(15):5613-5627. PubMed ID: 31377745
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Shiota M; Endo S; Fujimoto N; Tsukahara S; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Eto M
Urol Oncol; 2020 Nov; 38(11):849.e11-849.e18. PubMed ID: 32712140
[TBL] [Abstract][Full Text] [Related]
39. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
40. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
